The company is committed to the development of new dosage forms of antineoplastic drugs and related products. The company is committed to the R & D and industrialization of improved new drugs for antineoplastic drugs, with high-tech talents with the background of polymer materials, pharmaceutical preparations and biology, and mastering the core and key technologies for the synthesis of nano-drug carriers and medicinal polymer excipients. The company's main research and development product is paclitaxel micelles. Paclitaxel micelle is an innovative lyophilized powder injection without polyoxyethylene castor oil and methoxy polyethylene glycol 2000-poly (lactide) copolymer as carrier.
CEO： Jingsong Zhou
Listing Date： 09/09/2021